Project Grant R61HL177451
Award Date
4/1/25
Completion Date
3/31/26
Dollars Obligated
$542K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Michigan, USA
Similar Awards
This $1,546,880 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research to investigate the regulation of the myofibroblast gene program in idiopathic pulmonary fibrosis (IPF). The key objectives are to:
Determine the "regulatory architecture" of open chromatin in myofibroblasts in IPF lungs, employing massively-parallel reporter assays to assess transcriptional activity of differentially-accessible...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $306,872 Project Grant (under CFDA 93.837 - Cardiovascular Diseases Research) to Novomedix LLC to develop novel small molecule therapeutics for the treatment of idiopathic pulmonary fibrosis (IPF) and other progressive pulmonary fibrotic diseases. The key objectives are to: 1) Confirm the efficacy of Novomedix's lead drug candidates in advanced cell-based assays, 2) Scale up production of the lead candidates, and 3) Demonstrate...
This $651,019 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) is focused on elucidating the mechanisms underlying dysfunctional epithelial repair in pulmonary fibrosis. The research aims to:
Identify factors that drive aberrant epithelial cell states in persistent lung fibrosis,
Determine the impact of hypoxia-inducible factor (HIF) signaling in preventing functional alveolar repair after...
This $5,715,866 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) aims to develop novel, transformative therapies to reduce the burden of pulmonary fibrosis (PF). The grant supports a multi-institutional research program consisting of 4 projects and 3 cores to investigate the mechanisms driving the initiation and early progression of pre-clinical PF. The key products and services to be delivered include:
Utilizing...
This Project Grant award of $1,193,262.00, provided by the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), supports research to develop a novel gene therapy treatment for idiopathic pulmonary fibrosis (IPF) using adeno-associated virus-mediated delivery of the SGPL1 gene.
The key products and services to be delivered under this award include:
Validating the efficacy of the SGPL1 gene therapy (AAV-SPL) in mouse models of IPF...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), supports the development of a novel, disease-modifying oral medicine for idiopathic pulmonary fibrosis (IPF). The primary objectives are to identify a clinical development candidate (CDC) compound that selectively and potently inhibits the myocardin-related transcription factor (MRTF) pathway, a critical pathway for the initiation and...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $827,753 to support research aimed at developing more effective gene-mapping methods for the rare polygenic disorder idiopathic pulmonary fibrosis (IPF). The grant recipient, The Children's Hospital Corporation (doing business as Boston Children's Hospital), will pursue three complementary strategies: (1) extending a...
This $774,585 federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to investigate the role of inflammatory fibroblasts in the development of pulmonary fibrosis. The project aims to: 1) characterize the emergence and persistence of inflammatory fibroblasts in different models of lung injury and fibrosis, 2) determine the mechanisms driving the transition of inflammatory...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), is funding the development of a novel antibody drug candidate to treat idiopathic pulmonary fibrosis (IPF). The goal is to create a targeted therapy that specifically binds to and inhibits fibrosis in affected lung tissues, while avoiding disruption of normal receptor function. The $356,250 in funding will support affinity maturation, liability...
This $604,115 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) will fund an observational study by The General Hospital Corporation (Massachusetts General Hospital) to determine if advanced PET and MRI imaging technologies can predict which individuals with non-IPF interstitial lung disease are at highest risk of developing progressive pulmonary fibrosis (PPF). The research aims to enable early...